MindBio Therapeutics (FRA:WF60) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:WF60 MindBio Therapeutics Corp FRA:WF60
37 GF Score
Price €0.13
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

MindBio Therapeutics Quality Rank Related Terms

FRA:WF60
37GF Score
MindBio Therapeutics Corp FRA:WF60
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Business Description

Other Exchanges MBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score

Get the complete analysis for FRA:WF60

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price